SCHEMBL480633

SCHEMBL480633

COC(=O)c1ccccc1-c1ccc(C(C)C(O)(c2ccnc(Cl)c2)C(F)(F)F)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.42
SLC6A4 P31645 3/20 0.42
PDK2 Q15119 1/20 0.41
BDKRB1 P46663 7/20 0.41
SLC6A2 P23975 1/20 0.40
HSD17B3 P37058 1/20 0.38
GRM5 P41594 1/20 0.36
ROCK2 O75116 1/20 0.36
CSF1R P07333 1/20 0.36
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
CDK5 Q00535 1/20 0.36
ROCK1 Q13464 1/20 0.36
SLK Q9H2G2 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
SDHB P21912 1/20 0.36
BRS3 P32247 1/20 0.35
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL733519 0.89 SLC6A3 (0.39) SLC6A3SLC6A4PDK2BDKRB1SLC6A2
SCHEMBL480901 0.87 BDKRB1 (0.45) BDKRB1
SCHEMBL479969 0.86 MET (0.36) PDK2BDKRB1
SCHEMBL752208 0.86 MET (0.36) PDK2BDKRB1
SCHEMBL755473 0.85 ROCK2 (0.39) PDK2ROCK2ROCK1
SCHEMBL479702 0.85 ROCK2 (0.39) PDK2ROCK2ROCK1
SCHEMBL480160 0.83 PDK1 (0.43) PDK2
SCHEMBL15789843 0.81 ROCK2 (0.37) ROCK2ROCK1
SCHEMBL15789752 0.80 AAK1 (0.38) ROCK2GSK3BROCK1
SCHEMBL479896 0.79 RXRA (0.37) ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411361-B1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-06-18 EP disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2411361-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 SLC6A3 1157/4885SLC6A4 525/4885PDK2 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.